These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 5072367)

  • 21. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
    Kim JH; Resende R; Wennekes T; Chen HM; Bance N; Buchini S; Watts AG; Pilling P; Streltsov VA; Petric M; Liggins R; Barrett S; McKimm-Breschkin JL; Niikura M; Withers SG
    Science; 2013 Apr; 340(6128):71-5. PubMed ID: 23429702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.
    Meindl P; Bodo G; Palese P; Schulman J; Tuppy H
    Virology; 1974 Apr; 58(2):457-63. PubMed ID: 4362431
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthesis of 3-episiastatin B analogues having anti-influenza virus activity.
    Nishimura Y; Umezawa Y; Kondo S; Takeuchi T; Mori K; Kijima-Suda I; Tomita K; Sugawara K; Nakamura K
    J Antibiot (Tokyo); 1993 Dec; 46(12):1883-9. PubMed ID: 8294247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Function of neuraminidase of influenza virus and anti influenza compounds by its inhibition].
    Yamashita M
    Tanpakushitsu Kakusan Koso; 2009 Aug; 54(10):1284-91. PubMed ID: 19663256
    [No Abstract]   [Full Text] [Related]  

  • 25. [Genetic markers and their interrelationships in influenza viruses. 3. The interrelationship between virulence and sensitivity to serum inhibitors, neuraminidase and eluting activity].
    Sokolov MI; Shvachkina VI; Molibog EV
    Vopr Virusol; 1970; 15(4):488-92. PubMed ID: 5505413
    [No Abstract]   [Full Text] [Related]  

  • 26. Executive summary of the 6th meeting of the WHO Expert Working Group of the GISRS for Surveillance of Antiviral Susceptibility.
    Wkly Epidemiol Rec; 2017 Oct; 92(41):611-2. PubMed ID: 29028165
    [No Abstract]   [Full Text] [Related]  

  • 27. A secondary sialic acid binding site on influenza virus neuraminidase: fact or fiction?
    Lai JC; Garcia JM; Dyason JC; Böhm R; Madge PD; Rose FJ; Nicholls JM; Peiris JS; Haselhorst T; von Itzstein M
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2221-4. PubMed ID: 22281708
    [No Abstract]   [Full Text] [Related]  

  • 28. Chemotherapeutic control of influenza.
    Stephenson I; Nicholson KG
    J Antimicrob Chemother; 1999 Jul; 44(1):6-10. PubMed ID: 10459804
    [No Abstract]   [Full Text] [Related]  

  • 29. [Neuraminic acid as a cell receptor for virus of influenza].
    Tsvetkova IV; Lipkind MA; Zakstsl'skaia LIa; Iusipova NA; Rozenfel'd EL
    Biokhimiia; 1967; 32(5):994-9. PubMed ID: 5599905
    [No Abstract]   [Full Text] [Related]  

  • 30. Km values of influenza virus neuraminidases for a new fluorogenic substrate, 4-methylumbelliferone N-acetyl neuraminic acid ketoside.
    Thomas JJ; Folger EC; Nist DL; Thomas BJ; Jones RH
    Anal Biochem; 1978 Aug; 88(2):461-7. PubMed ID: 211875
    [No Abstract]   [Full Text] [Related]  

  • 31. Influenza virus resistance to antiviral therapy.
    van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A
    Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Peramivir. A new and potent neuraminidase inhibitor for the treatment of influenza].
    Reina J
    Rev Esp Quimioter; 2006 Dec; 19(4):317-22. PubMed ID: 17235399
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect on influenza virus of a modified Francis inhibitor and its acetone-soluble fraction. 3. Experiments on the mouse lung.
    Hollós I
    Acta Microbiol Acad Sci Hung; 1969; 16(2):113-22. PubMed ID: 5377767
    [No Abstract]   [Full Text] [Related]  

  • 34. The antiviral activity of caprochlorone.
    Stanfield FJ; Haff RF; Stewart RC
    Proc Soc Exp Biol Med; 1967 May; 125(1):297-303. PubMed ID: 6027546
    [No Abstract]   [Full Text] [Related]  

  • 35. The inhibition of neuraminidase and antiviral action.
    Edmond JD; Johnston RG; Kidd D; Rylance HJ; Sommerville RG
    Br J Pharmacol Chemother; 1966 Aug; 27(2):415-26. PubMed ID: 5967371
    [No Abstract]   [Full Text] [Related]  

  • 36. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
    Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A study of the active site of influenza virus sialidase: an approach to the rational design of novel anti-influenza drugs.
    von Itzstein M; Dyason JC; Oliver SW; White HF; Wu WY; Kok GB; Pegg MS
    J Med Chem; 1996 Jan; 39(2):388-91. PubMed ID: 8558506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coupled-enzyme system for measuring viral neuraminidase activity.
    Ziegler DW; Hutchinson HD
    Appl Microbiol; 1972 Jun; 23(6):1060-6. PubMed ID: 4114435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
    Wen WH; Lin M; Su CY; Wang SY; Cheng YS; Fang JM; Wong CH
    J Med Chem; 2009 Aug; 52(15):4903-10. PubMed ID: 19522501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differences in splitting capacity of virus and V. cholerae neuraminidases on sialic acid type substrates.
    Drzeniek R
    Biochem Biophys Res Commun; 1967 Mar; 26(6):631-8. PubMed ID: 6030973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.